Greywolf Therapeutics
Kate Anderton is an R&D Project Manager at Greywolf Therapeutics, where responsibilities include supporting preclinical studies from H2L through IND-enabling studies since March 2020. Prior experience includes serving as a Scientific Editor at AZoNetwork, creating content for the medical and life sciences sector, and working as a Microbiology Intern at MICROBIOLOGICAL SOLUTIONS LIMITED and GSK, where microbiological assessments were conducted. Kate's academic background includes a Biomedical Science B.Sc. from Lancaster University, complemented by a summer program at Radboud Summer School in July 2022.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.